Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution
文献类型：期刊论文
| 作者 | Yu, Haifeng3,4; Kong, Haiying1; Li, Cong3,4; Dong, Xiaowu2; Wu, Yizhe2; Zhuang, Yuxin2; Han, Shuiyun3,4; Lei, Tao3,4; Yang, Haiyan3,4 |
| 刊名 | TRANSLATIONAL CANCER RESEARCH
 |
| 出版日期 | 2021-05-01 |
| 卷号 | 10 |
| 关键词 | Primary central nervous system lymphoma ( PCNSL) Bruton's tyrosine kinase (BTK) ibrutinib zanubrutinib tirabrutinib |
| ISSN号 | 2218-676X |
| DOI | 10.21037/tcr-21-50 |
| 通讯作者 | Lei, Tao(leitao070713@sohu.com) ; Yang, Haiyan(haiyanyang1125@163.com) |
| 英文摘要 | Background: Primary central nervous system lymphoma (PCNSL) is an aggressive lymphoma confined to central nervous system. Current treatments including surgery, chemotherapy and whole-brain radiotherapy often fail to achieve satisfactory effect, especially in elderly. As a regimen in targeted therapy, Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been tested in several clinical trials against PCNSL, offering hope for patients unfit for chemotherapy. We aim to evaluate and compare the anti-PCNSL ability of three different BTK inhibitors, ibrutinib, zanubrutinib and tirabrutinib, providing direct evidence for the targeted therapy of PCNSL. Methods: Retrospective study was done on patients who received ibrutinib-based therapy in our hospital. Cerebrospinal fluid (CSF) from one patient was collected to measure the concentration of ibrutinib. Inhibition assay and apoptosis assay were done on lymphoma cells to determine the anti-tumoral effects of three inhibitors. Pharmacokinetic study was conducted to evaluate their ability in penetrating blood brain barrier and distributing in brain. Results: In retrospective study, we found three patients with PCNSL who had good clinical response to ibrutinib-based therapy (2 complete remission, 1 partial remission), which further support the use of BTK inhibitors in PCNSL. In vitro studies show that ibrutinib has the best anti-tumoral ability among three inhibitors. In vivo study on pharmacokinetic profiles indicate that both ibrutinib and tirabrutinib are good in distributing in brain parenchyma. Conclusions: In conclusion, our study results suggest that BTK inhibitors can be promising candidates for PCNSL treatment, preferring the use of ibrutinib and tirabrutinib as anti-PCNSL agents among the three inhibitors. |
| WOS关键词 | IBRUTINIB ; CHALLENGE |
| 资助项目 | Science and Technology Program of Traditional Chinese Medicinee, and Zhejiang[2021ZB038] ; Zhejiang Provincial Medicine and Health Science Fund[2021KY105] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000656696500003 |
| 出版者 | AME PUBL CO |
| 资助机构 | Science and Technology Program of Traditional Chinese Medicinee, and Zhejiang ; Zhejiang Provincial Medicine and Health Science Fund |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/123762]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Lei, Tao; Yang, Haiyan |
| 作者单位 | 1.Hangzhou Hanggang Hosp, Dept Pharm, Zhejiang Med & Hlth Grp, Hangzhou Hosp, Hangzhou, Peoples R China 2.Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou Inst Innovat Med, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Dept Lymphoma, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 4.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yu, Haifeng,Kong, Haiying,Li, Cong,et al. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution[J]. TRANSLATIONAL CANCER RESEARCH,2021,10. |
| APA | Yu, Haifeng.,Kong, Haiying.,Li, Cong.,Dong, Xiaowu.,Wu, Yizhe.,...&Yang, Haiyan.(2021).Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.TRANSLATIONAL CANCER RESEARCH,10. |
| MLA | Yu, Haifeng,et al."Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution".TRANSLATIONAL CANCER RESEARCH 10(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。